Thalidomide manufacturer knew of birth defect risks but continued marketing the drug worldwide

In the late 1950s, a West German pharmaceutical company called Chemie Grunenthal introduced a new sedative to the market with a promise that seemed almost too good to be true: a safe, non-toxic sleeping pill that wouldn't cause overdose deaths, even in large doses. The drug was called thalidomide, and within years it would become one of the most devastating pharmaceutical scandals of the modern era.

The original claim was simple and powerful: thalidomide was safe for everyone, including pregnant women. Chemie Grunenthal marketed it aggressively across Europe, Canada, and other parts of the world as the ideal sedative for anxiety, insomnia, and morning sickness. Doctors prescribed it widely. Pregnant women took it believing they were choosing the safest option available. The company's marketing materials promised efficacy without danger.

But even as thalidomide was being distributed to hundreds of thousands of patients, Chemie Grunenthal had received reports of a serious problem. Medical professionals had documented cases of peripheral neuropathy—severe nerve damage causing numbness, tingling, and long-term disability—in patients taking the drug. These adverse reports reached company leadership, yet the company continued marketing thalidomide globally without warning doctors or patients about the risks. Internal documents would later reveal that the company knew of these dangers but chose to suppress the information rather than halt sales.

The consequence was catastrophic. Between 1957 and 1962, an estimated 10,000 or more children were born with severe limb deformities—a condition now known as thalidomide embryopathy. Children were born with flipper-like appendages, missing fingers, shortened limbs, and other devastating birth defects. Many suffered additional organ damage. The scale of the tragedy became undeniable only when doctors began connecting the cases and linking them to maternal thalidomide use during pregnancy.

The official response from authorities was fragmented. In most countries, regulators had accepted the company's safety assurances and approved the drug without demanding rigorous testing. However, at the U.S. Food and Drug Administration, a single reviewer named Dr. Frances Oldham Kelsey refused to approve thalidomide for the American market. Despite pressure from the drug manufacturer and even from her own FDA colleagues, Kelsey insisted that the available safety data was insufficient. Her skepticism, rooted in careful scientific judgment rather than perfect foresight, proved prescient. The United States was largely spared the epidemic of birth defects that devastated other nations.